<DOC>
	<DOCNO>NCT01878344</DOCNO>
	<brief_summary>The aim study evaluate effect N-acetyl cysteine major cardiac cerebral event patient undergo primary percutaneous coronary intervention moderate high risk contrast induce nephropathy . In sub-group patient coronary flow reserve evaluate .</brief_summary>
	<brief_title>Effects N-acetyl Cysteine During Primary Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Patients Acute ST Elevation Myocardial Infarction undergo Primary Percutaneous Coronary intervention Who Have Moderate High Risk For Contrast Induced Nephropathy ( Mehran Score â‰¥5 ) Patients &gt; 18 year old moderate high risk contrast induce nephropathy undergo percutaneous coronary intervention Low risk contrast induce nephropathy ( Mehran Score &lt; 5 ) Use nephrotoxic agent ( NSAIDs , aminoglycosides , recent contrast injection ... ) Infection Pregnancy , Lactation Renal failure require dialysis Hepatic failure Allergy NAC History Asthma Chronic nitrate usage Malignancy Use corticosteroid Leucocytosis , Thrombocytosis , Anemia Blood pressure &gt; 180/100mmHg despite antihypertensive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>